ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010. The conference is being held at the Waldorf=Astoria in New York City.
Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17, 2010. The conference is being held at the St. Regis Hotel in New York City.
Mr. Rowland will also present at the 4th Annual Maxim Group Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010. The conference is being held at the Grand Hyatt in New York City.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com  and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing